cerrar
Tagged with Disease

Orphan Drugs in the USA: A Snapshot
80 orphan drugs (those drugs intended to treat diseases so rare that sponsors are reluctant to develop them under usual marketing conditions) were…

How Beneficial Is The Recent Price Control Exemption For…
Anay Shukla leads the pharmaceutical, life sciences, med-tech and healthcare practice at Nishith Desai Associates, a leading Indian law firm. In this…

Korea to Strengthen Support for Rare Disease Patients
This week, the Korean Ministry of Food and Drug Safety announced that it would enhance drug safety management and make a new, streamlined review…

Davide Dalle Fusine – General Manager, Chiesi China
Davide Dalle Fusine, general manager for Chiesi China, shares the key milestones for the company in the past five years, their leadership position in…

Canada: Targeting Rare Diseases
The research areas in which Canada has the potential to excel are numerous, one being the world of genomics. The stem cell itself having been…

Franck Puget – Managing Director, CSL Behring France
Franck Puget, managing director for CSL Behring in France, discusses the blood plasma specialist’s commitment to France, building bridges with…

Perspectives from J.P. Morgan’s 2019 Health Care Investor…
Our contributor at large, David Crean, Managing Director for Objective Capital Partners, attended J.P. Morgan's 2019 Health Care Investor…

Mythbusting: Patient Access to Rare Disease Treatments
After her son was diagnosed with SYNGAP1 – an extremely rare gene mutation – Monica founded Bridge the Gap – SYNGAP Education and Research…

Giuseppe Chiericatti – General Manager, Chiesi Spain
Giuseppe Chiericatti of Chiesi Spain talks strategy, the development of the affiliate and shifting attitudes towards rare diseases in Spain.…

PJ Brooks – Program Officer, Division of Clinical Innovation…
PJ Brooks PhD, program director in the Office of Rare Diseases Research at the National Center for Advancing Translational Sciences (NCATS), National…

Orphan Drugs in Europe: A Snapshot
125 medicines for rare diseases were approved by the EMA between 2004 and 2014, of which 71 were granted orphan drug status. This chart shows the…

Levent Canyurt – CEO & Founder, BIEM Ilac, Turkey
Levent Canyurt, CEO and founder of BIEM Ilac, shares how he transformed the company from a domestic pharmaceutical distributor into an international…
We use cookies to ensure that we give you the best experience on our site. For more info

See our Cookie Privacy Policy Here